FindTrial
Sign In

A study to see the result of blood products in repigmentation in stable vitiligo.

A hospital based study to compare the efficacy of platelet rich plasma therapy against platelet poor plasma therapy with concurrent oral PUVAsol therapy in patients of stable vitiligo vulgaris.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/04/013434
Enrollment
10
Registered
2018-04-24
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Stable Vitiligo

Interventions

Intervention1: Platelet rich plasma with PUVAsol: Patients plasma with atleast 4 fold higher platelet count from baseline will be injected intradermally in a dose of 0.05ML/INJECTION, 0.5 CM apart. Th

Sponsors

Shri Ram Murti Smarak Institute Of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: PATIENTS WITH STABLE VITILIGO PATCHES FOR ATLEAST 6 MONTHS. PATIENTS WILLING TO CONSENT, WILLING FOR INVESTIGATION, TREATMENT AND FOLLOW UP. ABSENCE OF KOEBNER PHENOMENON.

Exclusion criteria

Exclusion criteria: Age less than 12 years. Pregnancy or lactation. Patient unsure of attending treatment schedule, history of bleeding diathesis, history of intake of drugs leading to coagulation disorders in the past 1 month, history of immunobullous disorders. Patients with any hepatic, renal or any other chronic systemic illness.

Design outcomes

Primary

MeasureTime frame
50 percent repigmentation in sites treated with platelet rich therapy and PUVAsol.Timepoint: At the end of 16 weeks.—

Secondary

MeasureTime frame
To compare the time taken for repigmentation in patches treated with platelet rich pplasma therapy with PUVAsol.Timepoint: At the end of 16 weeks.—

Countries

India

Contacts

Public ContactDr Neni Agarwal

SHRI RAM MURTI SMARAK INSTITUTE OF MEDICAL SCIENCES

drpratikg.srmsims@gmail.com9458702263

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026